All In Biotech

Drug Trial Radar · NCT02605122

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia

Last checked: Nov 19, 2026Latest source record: Jan 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

97

Actual

Start

Apr 2016

Primary completion

Mar 21, 2018

Study completion Mar 21, 2018

Sponsor

Lead sponsor
Melinta Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Nov 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).

Conditions

  • Community-acquired Bacterial Pneumonia

Interventions

  • SolithromycinDrug

  • Standard of CareDrug

    Age- and weight-based dosing as appropriate per sites standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overview of Adverse Events By Treatment ArmTime frame: Up to 28 days post-treatment

Locations

58 sites in 6 countries. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Tampa, Florida

  • Site not named

    Louisville, Kentucky

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Durham, North Carolina

  • Site not named

    Greenville, North Carolina

  • Site not named

    Toledo, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Hershey, Pennsylvania

  • Site not named

    Memphis, Tennessee

  • Site not named

    Amarillo, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Splendora, Texas

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Richmond, Virginia

  • Site not named

    Roanoke, Virginia

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Rousse, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Vratsa, Bulgaria

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Cegléd, Hungary

  • Site not named

    Debrecen, Hungary

  • Site not named

    Győr, Hungary

  • Site not named

    Gyula, Hungary

  • Site not named

    Mosdós, Hungary

  • Site not named

    Nagykanizsa, Hungary

  • Site not named

    Nyíregyháza, Hungary

  • Site not named

    Szeged, Hungary

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.